Ignite Creation Date:
2024-05-06 @ 1:54 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04150887
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-09
First Post:
2019-11-01
Brief Title:
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
Sponsor:
OncoVerity Inc
Organization:
OncoVerity Inc
Study Overview
Official Title:
An Open-label Multicenter Phase 1b Study of OV-1001 Cusatuzumab Anti-CD70 Monoclonal Antibody in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ELEVATE
Brief Summary:
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-002808-41 | EUDRACT_NUMBER | None | None |
| ELEV20235 | OTHER | None | None |
| 74494550AML1003 | OTHER | Janssen Research Development LLC | None |